Anika Therapeutics(US:ANIK) Globenewswireยท2025-09-25 21:43Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Anika Therapeutics, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on whether Anika has engaged in unlawful practices that may have led to financial losses for investors [1][2]. - Anika's stockholders who have suffered losses are encouraged to contact the law firm for further discussion on their legal rights [3]. Company Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation across various courts in the U.S. [4]. Recent Company Events - On July 30, 2025, Anika announced topline results from a pivotal clinical trial of Hyalofast, which did not meet its pre-specified co-primary endpoints, leading to a significant drop in stock price [6]. - Following the announcement, Anika's stock price fell by $3.06 per share, or 27.42%, closing at $8.10 per share [6].